How to Invest in Healthcare Stocks 2026: EU Investor Guide

Quick Answer

Healthcare is a structurally defensive sector that has historically delivered mid to high single digit annualised returns with lower drawdowns than the broad market in recessions. EU investors can build exposure across four sub-sectors: big pharma (Eli Lilly, Novo Nordisk, J&J, Pfizer, Roche, Novartis, Bayer), biotech (Vertex, Regeneron, Moderna, BioNTech, Argenx), medical devices (Abbott, Medtronic, Stryker, Intuitive Surgical, Siemens Healthineers) and managed care (UnitedHealth, Elevance). The dominant 2024-2026 theme is the GLP-1 obesity revolution led by Eli Lilly (Mounjaro/Zepbound) and Novo Nordisk (Ozempic/Wegovy). UCITS ETFs available for EU investors include IXJ (global healthcare), and EU-listed iShares MSCI Health Care equivalents. A 5-8% healthcare allocation provides ballast against cyclical equity risk.

---

Top Healthcare Stocks and ETFs at a Glance

Numbers are May 2026 estimates for context. Verify before investing.

---

Methodology

Universe last revised on 2026-05-07. Selection captures companies with disclosed healthcare revenue greater than $5 billion or strategic franchise position (Argenx FcRn, BioNTech mRNA). Big pharma names tracked through quarterly results, FDA and EMA approval calendars and patent expiry waterfalls. Biotech weighted toward de-risked late-stage and approved-product names rather than pre-clinical. ETF universe limited to UCITS-eligible products available on Euronext, Xetra, LSE and SIX. Listed market caps are May 2026 estimates rounded for context.

---

Sector Thesis: Why Healthcare Now

Bull Case

Demographics are mathematical. The over-65 population in the EU and US continues to grow and consumes 3-4x the per-capita healthcare spending of the under-65 cohort. This demand curve is the closest thing to deterministic forecasting any large sector enjoys.

GLP-1 is the largest pharma launch in history. Combined Eli Lilly Mounjaro/Zepbound and Novo Nordisk Ozempic/Wegovy revenue exceeded $50 billion in 2025 and consensus 2030 revenue for the GLP-1 class exceeds $150 billion. Indications continue to expand from diabetes to obesity, cardiovascular outcomes, sleep apnea, MASH and addiction.

Defensive in recessions. From 2000 onward, the global healthcare sector has consistently produced lower-amplitude drawdowns than the broad market in recessions. Cancer, diabetes and cardiovascular disease budgets are last to be cut.

Innovation pipeline depth. ADC (antibody-drug conjugates), TCEs (T-cell engagers), siRNA, gene therapy and AI-driven drug discovery have meaningfully expanded the modality toolkit. Late-stage 2026-28 readouts include obesity outcomes data, Alzheimer's Aβ disease modifiers and oral GLP-1.

Bear Case

Drug pricing political risk. The US Inflation Reduction Act Medicare negotiation list expanded in 2025 and 2026 and adds margin pressure to legacy pharma franchises. EU member states continue to negotiate aggressively on price.

Patent cliffs are large. Keytruda (~$30B revenue line) faces biosimilar entry from 2028. Eylea, Stelara and Eliquis already entered or are entering biosimilar competition.

GLP-1 margin compression. Generic semaglutide entry in select markets from 2026, oral GLP-1 from competitors, and tirzepatide capacity constraints all introduce mix risk.

Elevated valuations on the leaders. Eli Lilly traded at over 50x forward earnings during 2024-25, expensive even on a structurally durable thesis.

Drivers to Watch

• Quarterly GLP-1 prescription data (IQVIA)
• FDA and EMA approval calendars
• US Medicare negotiation list updates (CMS)
• Biotech XBI vs broad market spread (proxy for risk-on biotech)
• M&A pace in mid-cap biotech

---

Sub-Sector Breakdown

Big Pharma

Eli Lilly (LLY). The decade's defining pharma franchise. Mounjaro and Zepbound (tirzepatide) exceeded $30 billion in 2025 revenue and capacity ramp continues through 2027. Pipeline includes retatrutide (next-generation GLP-1 + GIP + glucagon triple agonist) and orforglipron (oral GLP-1). Concerns: valuation, capacity and competitive entry.

Novo Nordisk (NVO). The Danish anchor of the GLP-1 thesis. Ozempic (diabetes) and Wegovy (obesity) drive roughly 70% of revenue. Stock derated meaningfully in late 2024 and 2025 on competitive concerns and SELECT trial reads. Listed in Copenhagen, EUR-equivalent exposure for EU investors. DKK currency.

Johnson & Johnson (JNJ). Diversified pharma plus medical devices following the consumer Kenvue spinoff in 2023. Stelara loss of exclusivity offset by Tremfya, Darzalex and Carvykti.

Pfizer (PFE). Post-COVID rerating priced in. Oncology pivot through Seagen acquisition needs to land. Yield around 6%.

Roche (ROG.SW). Swiss diagnostics and oncology giant. Tecentriq, Hemlibra, Ocrevus anchor the franchise. Diagnostics business adds defensive ballast.

Novartis (NOVN.SW). Pure innovative medicines following the Sandoz generics spinoff in 2023. Pipeline includes Pluvicto, Cosentyx, Entresto.

Bayer (BAYN.DE). Deep value with persistent litigation overhang on glyphosate. Crop science anchor.

AstraZeneca (AZN). Oncology and rare disease leader. Strong China exposure adds growth optionality.

GSK. Vaccines, HIV, respiratory franchises.

Biotech

Vertex Pharmaceuticals (VRTX). Cystic fibrosis franchise generates over $11 billion annual revenue with no near-term competition. Casgevy (ex-CRISPR) for sickle cell disease, plus pain and APOL1 kidney disease pipeline.

Regeneron (REGN). Eylea and Dupixent flagship franchises. Eylea facing biosimilar entry; Dupixent continues to expand indications.

Moderna (MRNA). Post-COVID derating, mRNA platform applied to RSV, flu and oncology personalised cancer vaccine partnership with Merck.

BioNTech (BNTX). German mRNA pioneer pivoting toward oncology. Listed Nasdaq.

Argenx (ARGX). Belgian biotech with Vyvgart (efgartigimod) FcRn franchise expanding from gMG to additional autoimmune indications. Listed on Euronext Brussels and Nasdaq.

Medical Devices

Abbott Laboratories (ABT). Diagnostics (FreeStyle Libre CGM), medical devices, nutrition. Defensive cash flow.

Medtronic (MDT). Ireland-domiciled, cardiac, neurological and surgical devices. Beneficial corporate domicile for EU investors.

Stryker (SYK). Orthopaedic implants and Mako surgical robotics.

Intuitive Surgical (ISRG). da Vinci surgical robotics monopoly with the Ion lung biopsy platform as pipeline upside.

Siemens Healthineers (SHL.DE). German imaging, diagnostics and Varian radiation oncology. EUR-denominated exposure.

Managed Care

UnitedHealth Group (UNH). Insurance plus Optum services + OptumRx PBM. Largest healthcare company by revenue. The defensive cash compounder of the sector with 2024-25 cybersecurity overhang now cleared.

Elevance Health (ELV). Anthem brand insurance with growing CarelonRx and Carelon services.

---

EU-Accessible UCITS ETFs

US-listed IXJ, IHE, XBI, XHE are not available to EU retail under MiFID II. The UCITS substitutes XDWH and HLT both deliver MSCI World Health Care exposure with 0.25-0.30% TER. BTEC is the UCITS biotech ticket that approximates XBI exposure for EU investors.

---

Risks for Healthcare Investors

• Drug pricing reform. US IRA and EU member-state price negotiation can compress branded margins.
• Patent cliffs. Major franchises (Keytruda 2028, Eliquis, Stelara) lose exclusivity.
• Clinical trial binary risk. Single-name biotech can move 50%+ on a phase 3 readout.
• Regulatory. FDA and EMA approval risk for novel modalities and accelerated approvals.
• Litigation. Bayer glyphosate, J&J talc tail risks.
• Currency. USD, CHF, GBP, DKK exposure all add EUR translation risk.

---

Worked Allocation: 5% Healthcare Tilt in a €100,000 Portfolio

A 5% sector tilt equals €5,000. One sensible split:

• €2,000 in a UCITS healthcare ETF (XDWH or HLT) for diversified core
• €1,000 in Eli Lilly for the GLP-1 leader
• €750 in Novo Nordisk (DKK-denominated EU anchor)
• €500 in UnitedHealth Group for managed care defence
• €750 in BTEC UCITS biotech for higher-beta innovation

This split keeps the largest single-name (Eli Lilly) below 1.0% of total portfolio while capturing the dominant pharma theme and biotech optionality.

---

Tax Handling for EU Investors

US-listed names (LLY, JNJ, PFE, ABT, MDT, SYK, ISRG, UNH, ELV, VRTX, REGN, MRNA) require W-8BEN for the 15% US dividend treaty rate.

Novo Nordisk (Denmark) carries 27% Danish withholding which is partially refundable through the relevant EU treaty. Holding NVO inside an Irish-domiciled UCITS ETF mitigates the second layer.

Roche (CHF) and Novartis (CHF) carry 35% Swiss withholding. The treaty refundable rate depends on residence: typically 15% remains and the remaining 20% requires an annual reclaim. UCITS ETFs handle the internal reclaim more efficiently than direct retail holding.

UK names (AZN, GSK) carry 0% UK withholding on dividends as a matter of domestic law for non-resident retail. EU investors pay only the residence-state tax.

For Polish residents the 19% Belka tax applies on capital gains and dividends after the foreign withholding credit. For German residents Abgeltungsteuer 25% plus solidarity applies with the Vorabpauschale on accumulating ETFs. Always verify with a local tax adviser.

---

Authoritative Sources

• Eli Lilly 2025 10-K and Q1 2026 release (investor.lilly.com)
• Novo Nordisk 2025 annual report (novonordisk.com/investors)
• IQVIA Institute Global Use of Medicines 2030 (iqvia.com)
• iShares IUHC and Xtrackers XDWH factsheets
• US CMS Medicare Drug Price Negotiation Program updates (cms.gov)

---

FAQ

Is Eli Lilly still a buy at this valuation? Forward P/E around 35-45x in May 2026 implies continued GLP-1 growth. Position sizing is more important than entry timing on this name.

Has Novo Nordisk lost its lead? Novo retains roughly half of GLP-1 prescription volume but Lilly's tirzepatide has gained obesity market share. Both belong in a healthcare sleeve.

Can EU investors buy XBI or IHE directly? No, both are US-listed and blocked under MiFID II. Use BTEC for biotech and XDWH for broad healthcare.

Is healthcare really defensive? Historically yes — global healthcare drew down materially less than the broad MSCI World during 2008, 2020 and 2022 corrections.

How big should my biotech allocation be? Most disciplined investors keep biotech under 2% of total portfolio given trial binary risk.

What about Chinese biotech? Hong Kong-listed BeiGene, WuXi Biologics and Innovent are not commonly held by EU retail given accounting and US export risk.

Are GLP-1s a fad? Multi-year cardiovascular and renal outcomes data (SELECT, FLOW) and adoption curves through 2026 suggest a sustained franchise rather than a fad.

---

TL;DR

• Four sub-sectors: pharma (LLY, NVO, JNJ, ROG, NOVN), biotech (VRTX, REGN, ARGX), devices (ABT, MDT, SYK, ISRG, SHL) and managed care (UNH, ELV).
• Eli Lilly at ~$700B market cap and Novo Nordisk at €420B anchor the GLP-1 thesis ($50B 2025 combined revenue).
• UCITS ETFs for EU investors: XDWH 0.25%, HLT 0.30%, IUHC 0.46%, BTEC for biotech.
• Healthcare has historically drawn down less than broad equities in recessions.
• A 5% sector tilt (€5,000 in a €100k portfolio) split across UCITS ETF, LLY, NVO, UNH and BTEC is defensible.
• Sign W-8BEN for US names; Swiss and Danish withholding require treaty reclaim.
• This guide is informational only and is not investment advice.